Halberd

Halberd Corporation (OTC PINK:HALB) is a publicly listed company on the OTC market, fully compliant with OTC market reporting requirements. It holds the global exclusive rights to patent-pending and PCT filings for in vitro treatments targeting COVID-19 and other medical conditions. It is a research-based company focused on discovering and developing drugs for various diseases. The company has developed in vitro treatments that are applicable to difficult-to-treat blood-borne and neurological disorders, including Coronavirus Disease 2019 (Covid-19), other viruses, Post-Traumatic Stress Disorder (PTSD), and cancer.